HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

The overexpressed HER2 is an important target for treatment with monoclonal antibody (mAb) trastuzumab, only in patients breast and gastric cancers, emerging therapeutic biomarker metastatic colorectal cancer (mCRC) treated anti-epidermal growth factor receptor (EGFR) mAbs cetuximab panitumumab. In this study, we investigated the relative expression predictive value of all human epidermal (HER) family members 144 cetuximab-treated wild type RAS mCRC. EGFR have also been examined 21-paired primary tumours their sites by immunohistochemistry. Of cases examined, 25%, 97%, 79%, 48%, 10% were positive EGFR, HER2, HER3, HER4 four HER members, respectively. was indicator poorer overall survival membranous HER3 3+ intensity associated a shorter progression free (PFS). contrast, cytoplasmic better PFS. 48% 71% cases, there discordance or one more paired related tumours, Our results implicate importance large prospective investigation level not (i.e., protein) but other as targets, response to therapy anti-EGFR forms inhibitors, both